{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:10:29Z","timestamp":1791911429612,"version":"4.3.4"},"reference-count":183,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Parasitic diseases represent a severe global burden, with current treatments often limited by toxicity, drug resistance, and suboptimal efficacy in chronic infections. This review examines the emerging role of triazole-based compounds, originally developed as antifungals, in advanced antiparasitic therapy. Their unique structural properties, particularly those of 1,2,3- and 1,2,4-triazole isomers, facilitate diverse binding interactions and favorable pharmacokinetics. By leveraging innovative synthetic approaches, such as click chemistry (copper-catalyzed azide\u2013alkyne cycloaddition) and structure-based design, researchers have repurposed and optimized triazole scaffolds to target essential parasite pathways, including sterol biosynthesis via CYP51 and other novel enzymatic routes. Preclinical studies in models of Chagas disease, leishmaniasis, malaria, and helminth infections demonstrate that derivatives like posaconazole, ravuconazole, and DSM265 exhibit potent in vitro and in vivo activity, although their primarily static effects have limited their success as monotherapies in chronic cases. Combination strategies and hybrid molecules have demonstrated the potential to enhance efficacy and mitigate drug resistance. Despite challenges in achieving complete parasite clearance and managing potential toxicity, interdisciplinary efforts across medicinal chemistry, parasitology, and clinical research highlight the significant potential of triazoles as components of next-generation, patient-friendly antiparasitic regimens. These findings support the further optimization and clinical evaluation of triazole-based agents to improve treatments for neglected parasitic diseases.<\/jats:p>","DOI":"10.3390\/tropicalmed10050142","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:10:46Z","timestamp":1747721446000},"page":"142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Progress and Prospects of Triazoles in Advanced Therapies for Parasitic Diseases"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8004-6918","authenticated-orcid":false,"given":"Jaime A.","family":"Isern","sequence":"first","affiliation":[{"name":"Leibniz-Forschungsinstitut f\u00fcr Molekulare Pharmakologie (FMP), Robert-R\u00f6ssle-Str. 10, 13125 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-0574","authenticated-orcid":false,"given":"Renzo","family":"Carlucci","sequence":"additional","affiliation":[{"name":"Instituto de Qu\u00edmica Rosario, Universidad Nacional de Rosario, CONICET, S2002LRK Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-1573","authenticated-orcid":false,"given":"Guillermo R.","family":"Labadie","sequence":"additional","affiliation":[{"name":"Instituto de Qu\u00edmica Rosario, Universidad Nacional de Rosario, CONICET, S2002LRK Rosario, Argentina"},{"name":"Departamento de Qu\u00edmica Org\u00e1nica, Facultad de Ciencias Bioqu\u00edmicas y Farmac\u00e9uticas, Universidad Nacional de Rosario, S2002LRK Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7463-1468","authenticated-orcid":false,"given":"Exequiel O. J.","family":"Porta","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, Faculty of Life Sciences, University College London (UCL), 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref_1","unstructured":"(2025, January 02). WHO. Available online: https:\/\/www.who.int\/health-topics\/neglected-tropical-diseases."},{"key":"ref_2","unstructured":"Holmes, K.K., Bertozzi, S., Bloom, B.R., and Jha, P. (2017). An Investment Case for Ending Neglected Tropical Diseases. Major Infectious Diseases, The International Bank for Reconstruction and Development\/The World Bank. [3rd ed.]. Chapter 17."},{"key":"ref_3","unstructured":"(2025, January 02). WHO. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12936-022-04303-6","article-title":"The economic burden of malaria: A systematic review","volume":"21","author":"Andrade","year":"2022","journal-title":"Malar. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40249-021-00919-z","article-title":"The economic impact of schistosomiasis","volume":"10","author":"Rinaldo","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4269\/ajtmh.15-0408","article-title":"Social and Economic Burden of Human Leishmaniasis","volume":"94","author":"Okwor","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.05.001","article-title":"Chagas disease in Europe: A review for the internist in the globalized world","volume":"43","author":"Antinori","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5334\/gh.1280","article-title":"The Burden of Chagas Disease in the Contemporary World: The RAISE Study","volume":"19","author":"Ribeiro","year":"2024","journal-title":"Glob. Heart"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Curtin, J.M., and Aronson, N.E. (2021). Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity. Microorganisms, 9.","DOI":"10.3390\/microorganisms9030578"},{"key":"ref_10","unstructured":"Global Burden of Disease Collaborative Network (2022). Global Burden of Disease Study 2021 (GBD 2021) Results, Institute for Health Metrics and Evaluation (IHME). Available online: https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Capela, R., Moreira, R., and Lopes, F. (2019). An Overview of Drug Resistance in Protozoal Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225748"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Brindha, J., Balamurali, M.M., and Chanda, K. (2021). An Overview on the Therapeutics of Neglected Infectious Diseases\u2013Leishmaniasis and Chagas Diseases. Front. Chem., 9.","DOI":"10.3389\/fchem.2021.622286"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1016\/S1473-3099(24)00141-5","article-title":"The Emergence of Artemisinin Partial Resistance in Africa: How Do We Respond?","volume":"24","author":"Rosenthal","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.36922\/itps.3721","article-title":"The Crucial Role of Drug Repositioning in Tackling Chagas Disease, Sleeping Sickness, and Leishmaniasis","volume":"7","author":"Porta","year":"2024","journal-title":"INNOSC Theranostics Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bioorg.2017.01.010","article-title":"Medicinal Attributes of 1,2,3-Triazoles: Current Developments","volume":"71","author":"Dheer","year":"2017","journal-title":"Bioorg. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dai, J., Tian, S., Yang, X., and Liu, Z. (2022). Synthesis Methods of 1,2,3-\/1,2,4-Triazoles: A Review. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.891484"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1358\/dot.2015.51.12.2421058","article-title":"Triazole Antifungals: A Review","volume":"51","author":"Peyton","year":"2015","journal-title":"Drugs Today"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1021\/bi300744z","article-title":"1,2,3-Triazole-Heme Interactions in Cytochrome P450: Functionally Competent Triazole\u2013Water\u2013Heme Complexes","volume":"51","author":"Conner","year":"2012","journal-title":"Biochemistry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112652","DOI":"10.1016\/j.ejmech.2020.112652","article-title":"An Insight on Medicinal Attributes of 1,2,4-Triazoles","volume":"205","author":"Aggarwal","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1017\/S0031182018000562","article-title":"CYP51 as Drug Targets for Fungi and Protozoan Parasites: Past, Present and Future","volume":"145","author":"Lepesheva","year":"2018","journal-title":"Parasitology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"116942","DOI":"10.1016\/j.ejmech.2024.116942","article-title":"Identification of Novel and Potent Triazoles Targeting CYP51 for Antifungal: Design, Synthesis, and Biological Study","volume":"280","author":"Sun","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"23916","DOI":"10.1074\/jbc.M115.677310","article-title":"Structure-Functional Characterization of Cytochrome P450 Sterol 14\u03b1-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs","volume":"290","author":"Hargrove","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Porta, E.O.J., Kalesh, K., and Steel, P.G. (2023). Navigating Drug Repurposing for Chagas Disease: Advances, Challenges, and Opportunities. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1233253"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a Strategy for the Discovery of New Anti-Leishmanials: The-State-of-the-Art","volume":"145","author":"Charlton","year":"2018","journal-title":"Parasitology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-385863-4.00004-6","article-title":"Targeting Trypanosoma cruzi Sterol 14\u03b1-Demethylase (CYP51)","volume":"75","author":"Lepesheva","year":"2011","journal-title":"Adv. Parasitol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click Chemistry: Diverse Chemical Function from a Few Good Reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1359-6446(03)02933-7","article-title":"The Growing Impact of Click Chemistry on Drug Discovery","volume":"8","author":"Kolb","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.bmc.2019.07.005","article-title":"1,2,3-Triazole-Containing Hybrids as Leads in Medicinal Chemistry: A Recent Overview","volume":"27","author":"Bozorov","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cmdc.201402233","article-title":"Are 1,4- and 1,5-Disubstituted 1,2,3-Triazoles Good Pharmacophoric Groups?","volume":"9","author":"Massarotti","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/17460441.2022.2129613","article-title":"The 1,2,3-Triazole \u201cAll-in-One\u201d Ring System in Drug Discovery: A Good Bioisostere, a Good Pharmacophore, a Good Linker, and a Versatile Synthetic Tool","volume":"17","author":"Lengerli","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2017.05.014","article-title":"The 1,2,3-Triazole Ring as a Bioisostere in Medicinal Chemistry","volume":"22","author":"Bonandi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Song, B., Park, E.Y., Kim, K.J., and Ki, S.H. (2022). Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics. Cancers, 14.","DOI":"10.3390\/cancers14194601"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpddr.2021.08.004","article-title":"Exploring the \u03b2-Tubulin Gene Family in a Benzimidazole-Resistant Parascaris univalens Population","volume":"17","author":"Martin","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e202300024","DOI":"10.1002\/cbdv.202300024","article-title":"1,2,3-Triazole Derivatives as an Emerging Scaffold for Antifungal Drug Development against Candida albicans: A Comprehensive Review","volume":"20","author":"Singh","year":"2023","journal-title":"Chem. Biodivers."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Matin, M.M., Matin, P., Rahman, M.R., Ben Hadda, T., Almalki, F.A., Mahmud, S., Ghoneim, M.M., Alruwaily, M., and Alshehri, S. (2022). Triazoles and Their Derivatives: Chemistry, Synthesis, and Therapeutic Applications. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.864286"},{"key":"ref_37","unstructured":"Humayun, M.J., and Wadhwa, R. (2025, February 28). Rufinamide, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557595\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1021\/acs.jmedchem.3c01097","article-title":"1,2,3-Triazoles in Biomolecular Crystallography: A Geometrical Data-Mining Approach","volume":"66","author":"Carlucci","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ejmech.2008.11.007","article-title":"Design, Synthesis, and Biological Evaluation of Novel Triazole Derivatives as Inhibitors of Cytochrome P450 14\u03b1-Demethylase","volume":"44","author":"Chai","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/AAC.02067-12","article-title":"Azole Affinity of Sterol 14\u03b1-Demethylase (CYP51) Enzymes from Candida albicans and Homo sapiens","volume":"57","author":"Warrilow","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpddr.2020.06.001","article-title":"Novel Structural CYP51 Mutation in Trypanosoma cruzi Associated with Multidrug Resistance to CYP51 Inhibitors and Reduced Infectivity","volume":"13","author":"Franco","year":"2020","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"113602","DOI":"10.1016\/j.ejmech.2021.113602","article-title":"A Review: Pharmacological Aspects of Metal Based 1,2,4-Triazole Derived Schiff Bases","volume":"222","author":"Zafar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e202400190","DOI":"10.1002\/tcr.202400190","article-title":"A Review on Chemistry and Methods of Synthesis of 1,2,4-Triazole Derivatives","volume":"25","author":"Cunha","year":"2025","journal-title":"Chem. Rec."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"36945","DOI":"10.1021\/acsomega.2c04883","article-title":"Versatile Synthetic Platform for 1,2,3-Triazole Chemistry","volume":"7","author":"Vala","year":"2022","journal-title":"ACS Omega"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"153518","DOI":"10.1016\/j.tetlet.2021.153518","article-title":"Recent Advances in the Chemistry of 1,2,4-Triazoles: Synthesis, Reactivity and Biological Activities","volume":"86","author":"Abdelli","year":"2021","journal-title":"Tetrahedron Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115254","DOI":"10.1016\/j.ejmech.2023.115254","article-title":"Recent Updates on 1,2,3-Triazole-Containing Hybrids with In Vivo Therapeutic Potential Against Cancers: A Mini-Review","volume":"251","author":"Zhao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"115699","DOI":"10.1016\/j.ejmech.2023.115699","article-title":"Current Development of 1,2,3-Triazole Derived Potential Antimalarial Scaffolds: Structure-Activity Relationship (SAR) and Bioactive Compounds","volume":"259","author":"Bhatti","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115694","DOI":"10.1016\/j.ejmech.2023.115694","article-title":"Triazole Hybrid Compounds: A New Frontier in Malaria Treatment","volume":"259","author":"Ravindar","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1055\/s-0037-1611712","article-title":"Heterogeneous Copper(I)-Catalyzed Cascade Addition\u2013Oxidative Cyclization of Nitriles with 2-Aminopyridines or Amidines: Efficient and Practical Synthesis of 1,2,4-Triazoles","volume":"51","author":"Xia","year":"2019","journal-title":"Synthesis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1002\/anie.200900942","article-title":"Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality","volume":"48","author":"Sletten","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.bioconjchem.4c00003","article-title":"Metal-Free Click-Chemistry: A Powerful Tool for Fabricating Hydrogels for Biomedical Applications","volume":"35","author":"Degirmenci","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1155\/2014\/340586","article-title":"Therapeutic Drug Monitoring for Triazoles: A Needs Assessment Review and Recommendations from a Canadian Perspective","volume":"25","author":"Laverdiere","year":"2014","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jaklov\u00e1 Dytrtov\u00e1, J., B\u011blono\u017en\u00edkov\u00e1, K., Jakl, M., Chmel\u00edk, J., Kova\u010d, I., and Ry\u0161lav\u00e1, H. (2023). Non-Target Biotransformation Enzymes as a Target for Triazole-Zinc Mixtures. Chem. Biol. Interact., 382.","DOI":"10.1016\/j.cbi.2023.110625"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the Use of Azole Antifungals in Hematology-Oncology Patients","volume":"36","author":"Azanza","year":"2023","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1086\/591459","article-title":"Drug interactions involving combination antiretroviral therapy and other anti-infective agents: Repercussions for resource-limited countries","volume":"198","author":"Dooley","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"3rd. New Perspectives on Antimicrobial Agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: Expanding the Scope of the Protein\u2013Ligand Interaction Profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Francisco, A.F., Jayawardhana, S., Olmo, F., Lewis, M.D., Wilkinson, S.R., Taylor, M.C., and Kelly, J.M. (2020). Challenges in Chagas Disease Drug Development. Molecules, 25.","DOI":"10.3390\/molecules25122799"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kessler, R.L., Soares, M.J., Probst, C.M., and Krieger, M.A. (2013). Trypanosoma cruzi Response to Sterol Biosynthesis Inhibitors: Morphophysiological Alterations Leading to Cell Death. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055497"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AAC.44.1.150-155.2000","article-title":"Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts","volume":"44","author":"Molina","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. cruzi Carriers: The STOP-CHAGAS Trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-Concept, Randomised, Placebo-Controlled Trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Calvet, C.M., Silva, T.A., Thomas, D., Suzuki, B., Hirata, K., Siqueira-Neto, J.L., and McKerrow, J.H. (2020). Long Term Follow-Up of Trypanosoma cruzi Infection and Chagas Disease Manifestations in Mice Treated with Benznidazole or Posaconazole. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008726"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Diniz Lde, F., Urbina, J.A., de Andrade, I.M., Mazzeti, A.L., Martins, T.A., Caldas, I.S., Talvani, A., Ribeiro, I., and Bahia, M.T. (2013). Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002367"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e02264-18","DOI":"10.1128\/AAC.02264-18","article-title":"Synergic Effect of Allopurinol in Combination with Nitroheterocyclic Compounds against Trypanosoma cruzi","volume":"63","author":"Mazzeti","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Almeida-Silva, J., Menezes, D.S., Fernandes, J.M.P., Almeida, M.C., Vasco-Dos-Santos, D.R., Saraiva, R.M., Vi\u00e7osa, A.L., Perez, S.A.C., Andrade, S.G., and Suarez-Fontes, A.M. (2022). The Repositioned Drugs Disulfiram\/Diethyldithiocarbamate Combined to Benznidazole: Searching for Chagas Disease Selective Therapy, Preventing Toxicity and Drug Resistance. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.926699"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e0110","DOI":"10.1097\/MD9.0000000000000110","article-title":"Disulfiram Repurposing in the Combined Chemotherapy of Chagas Disease: A Protocol for Phase I\/II Clinical Trial","volume":"2","author":"Saraiva","year":"2021","journal-title":"Med. Case Rep. Study Protoc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.steroids.2013.10.010","article-title":"Click Chemistry Decoration of Amino Sterols as a Promising Strategy to Develop New Leishmanicidal Drugs","volume":"79","author":"Porta","year":"2014","journal-title":"Steroids"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1039\/C7MD00008A","article-title":"Antitrypanosomal and Antileishmanial Activity of Prenyl-1,2,3-Triazoles","volume":"8","author":"Porta","year":"2017","journal-title":"Medchemcomm"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"115378","DOI":"10.1016\/j.ejmech.2023.115378","article-title":"Systematic Study of 1,2,3-Triazolyl Sterols for the Development of New Drugs against Parasitic Neglected Tropical Diseases","volume":"254","author":"Porta","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Chen, C.K., Leung, S.S., Guilbert, C., Jacobson, M.P., McKerrow, J.H., and Podust, L.M. (2010). Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000651"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1128\/AAC.00537-10","article-title":"Tolerance of Benznidazole in Treatment of Chagas\u2019 Disease in Adults","volume":"54","author":"Pinazo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-0-387-77570-8_6","article-title":"Sterol 14-Demethylase Inhibitors for Trypanosoma cruzi Infections","volume":"625","author":"Buckner","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.01742-09","article-title":"Effects of Ravuconazole Treatment on Parasite Load and Immune Response in Dogs Experimentally Infected with Trypanosoma cruzi","volume":"54","author":"Caldas","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2009.10.023","article-title":"Specific Chemotherapy of Chagas Disease: Relevance, Current Limitations and New Approaches","volume":"115","author":"Urbina","year":"2010","journal-title":"Acta Trop."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.3314\/mmj.16-00006","article-title":"Potential of Ravuconazole and Its Prodrugs as the New Oral Therapeutics for Onychomycosis","volume":"57","author":"Yamaguchi","year":"2016","journal-title":"Med. Mycol. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e00401-18","DOI":"10.1128\/AAC.00401-18","article-title":"Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice","volume":"62","author":"Diniz","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e02150-19","DOI":"10.1128\/AAC.02150-19","article-title":"Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers","volume":"65","author":"Ribeiro","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102278","DOI":"10.1016\/j.parint.2020.102278","article-title":"Development of E1224 by Leveraging a Strategic Partnership for the Medicines Creation Against Neglected Tropical Diseases","volume":"81","author":"Hata","year":"2021","journal-title":"Parasitol. Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1473-3099(20)30844-6","article-title":"New Regimens of Benznidazole Monotherapy and in Combination with Fosravuconazole for Treatment of Chagas Disease (BENDITA): A Phase 2, Double-Blind, Randomised Trial","volume":"21","author":"Torrico","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas\u2019 Disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An Update on Pharmacotherapy for Leishmaniasis","volume":"16","author":"Sundar","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1128\/AAC.02405-14","article-title":"Studies on the Antileishmanial Mechanism of Action of the Arylimidamide DB766: Azole Interactions and Role of CYP5122A1","volume":"58","author":"Pandharkar","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Ponte-Sucre, A., Gamarro, F., Dujardin, J.C., Barrett, M.P., L\u00f3pez-V\u00e9lez, R., Garc\u00eda-Hern\u00e1ndez, R., Pountain, A.W., Mwenechanya, R., and Papadopoulou, B. (2017). Drug Resistance and Treatment Failure in Leishmaniasis: A 21st Century Challenge. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006052"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/0140-6736(90)93272-Q","article-title":"Ketoconazole in Treatment of Visceral Leishmaniasis","volume":"336","author":"Wali","year":"1990","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-4632.2004.02183.x","article-title":"Itraconazole in the Treatment of New World Mucocutaneous Leishmaniasis","volume":"43","author":"Calvopina","year":"2004","journal-title":"Int. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpddr.2022.07.003","article-title":"Sterol Profiling of Leishmania Parasites Using a New HPLC-Tandem Mass Spectrometry-Based Method and Antifungal Azoles as Chemical Probes Reveals a Key Intermediate Sterol That Supports a Branched Ergosterol Biosynthetic Pathway","volume":"20","author":"Feng","year":"2022","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/jm050691f","article-title":"Amiodarone Has Intrinsic Anti-Trypanosoma cruzi Activity and Acts Synergistically with Posaconazole","volume":"49","author":"Benaim","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/AAC.43.12.2910","article-title":"Efficacy of the Triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous and Visceral Leishmaniases","volume":"43","author":"Graybill","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e0142521","DOI":"10.1128\/AAC.01425-21","article-title":"Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection","volume":"66","author":"Quintero","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","first-page":"128","article-title":"Repurposing Lansoprazole and Posaconazole to Treat Leishmaniasis: Integration of In Vitro Testing, Pharmacological Corroboration, and Mechanisms of Action","volume":"30","author":"Gupta","year":"2022","journal-title":"J. Food Drug Anal."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1128\/AAC.01498-10","article-title":"Successful Treatment of Old World Cutaneous Leishmaniasis Caused by Leishmania infantum with Posaconazole","volume":"55","author":"Stavropoulos","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jdcr.2021.12.028","article-title":"Cutaneous Leishmaniasis Due to Leishmania aethiopica: A Therapeutic Challenge","volume":"20","author":"Mengeot","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.annder.2019.09.600","article-title":"Leishmaniose Cutan\u00e9e du Vermillon avec Atteinte Muqueuse de la L\u00e8vre Sup\u00e9rieure [Cutaneous Leishmaniasis of the Vermilion Border of the Upper Lip Extending to the Oral Mucosa]","volume":"147","author":"Elfatoiki","year":"2020","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e12976","DOI":"10.1111\/dth.12976","article-title":"Cutaneous Sporotrichoid Leishmaniasis Treated with Oral Fluconazole","volume":"32","author":"Benzaquen","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cid\/ciw662","article-title":"Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial","volume":"64","author":"Prates","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Francesconi, V.A., Francesconi, F., Ramasawmy, R., Romero, G.A.S., and Alecrim, M.D.G.C. (2018). Failure of Fluconazole in Treating Cutaneous Leishmaniasis Caused by Leishmania guyanensis in the Brazilian Amazon: An Open, Nonrandomized Phase 2 Trial. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006225"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jiac.2021.02.011","article-title":"Efficacy of Amiodarone and Voriconazole Combination Therapy in Cutaneous Leishmaniasis in the Mice Experimentally Infected with Leishmania major","volume":"27","author":"Bahrami","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Galv\u00e3o, E.L., Rabello, A., and Cota, G.F. (2017). Efficacy of Azole Therapy for Tegumentary Leishmaniasis: A Systematic Review and Meta-Analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186117"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"de Macedo-Silva, S.T., Urbina, J.A., de Souza, W., and Rodrigues, J.C. (2013). In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083247"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: A Broad-Spectrum Triazole Antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4269\/ajtmh.22-0733","article-title":"Treatment of Cutaneous Leishmaniasis with Allopurinol Plus Itraconazole in Iran","volume":"108","author":"Derakhshan","year":"2023","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"466","DOI":"10.25259\/IJMR_569_2024","article-title":"Possibility of Re-Purposing Antifungal Drugs Posaconazole & Isavuconazole against Promastigote Form of Leishmania major","volume":"160","author":"Bhusal","year":"2024","journal-title":"Indian J. Med. Res."},{"key":"ref_104","first-page":"61","article-title":"Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program","volume":"106","author":"Tarral","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/BJ20111849","article-title":"Novel sterol metabolic network of Trypanosoma brucei procyclic and bloodstream forms","volume":"443","author":"Nes","year":"2012","journal-title":"Biochem. J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/mmi.13854","article-title":"Beyond immune escape: A variant surface glycoprotein causes suramin resistance in Trypanosoma brucei","volume":"107","author":"Wiedemar","year":"2018","journal-title":"Mol. Microbiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0166-6851(90)90182-L","article-title":"Selective inhibition of the uptake by bloodstream form Trypanosoma brucei brucei of serum lipoprotein-associated phospholipid and cholesteryl ester","volume":"41","author":"Vandeweerd","year":"1990","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8896","DOI":"10.1021\/acs.jmedchem.3c00509","article-title":"Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static-Cidal Screening of Analogues","volume":"66","author":"Cleghorn","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"108711","DOI":"10.1016\/j.exppara.2024.108711","article-title":"In Vitro Antitrypanosomal Activity of Synthesized Nitrofurantoin-Triazole Hybrids against Trypanosoma Species Causing Animal African Trypanosomosis","volume":"259","author":"Seetsi","year":"2024","journal-title":"Exp. Parasitol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-022-05581-4","article-title":"The Pipeline for Drugs for Control and Elimination of Neglected Tropical Diseases: 1. Anti-Infective Drugs for Regulatory Registration","volume":"16","author":"Pfarr","year":"2023","journal-title":"Parasit. Vectors"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1473-3099(22)00660-0","article-title":"Efficacy and Safety of Acoziborole in Patients with Human African Trypanosomiasis Caused by Trypanosoma brucei gambiense: A Multicentre, Open-Label, Single-Arm, Phase 2\/3 Trial","volume":"23","author":"Kalonji","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejmech.2019.01.047","article-title":"Triazole Derivatives and Their Antiplasmodial and Antimalarial Activities","volume":"166","author":"Chu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Iso-O, N., Komatsuya, K., Tokumasu, F., Isoo, N., Ishigaki, T., Yasui, H., Yotsuyanagi, H., Hara, M., and Kita, K. (2021). Malaria Parasites Hijack Host Receptors from Exosomes to Capture Lipoproteins. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.749153"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12936-016-1130-z","article-title":"Changes in lipid composition during sexual development of the malaria parasite Plasmodium falciparum","volume":"15","author":"Tran","year":"2016","journal-title":"Malar. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/jacsau.3c00716","article-title":"Access to Artemisinin-Triazole Antimalarials via Organo-Click Reaction: High In Vitro\/In Vivo Activity against Multi-Drug-Resistant Malaria Parasites","volume":"4","author":"Herrmann","year":"2024","journal-title":"JACS Au"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"115400","DOI":"10.1016\/j.ejmech.2023.115400","article-title":"Biological Activity of 1,2,3-Triazole-2-amino-1,4-naphthoquinone Derivatives and Their Evaluation as Therapeutic Strategy for Malaria Control","volume":"255","author":"Ferreira","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"138882","DOI":"10.1016\/j.molstruc.2024.138882","article-title":"Quinoline-1,2,3-Triazole Hybrids: Design, Synthesis, Antimalarial and Antimicrobial Evaluation","volume":"1316","author":"Yadav","year":"2024","journal-title":"J. Mol. Struct."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Mili\u0107evi\u0107, D., Kimmel, R., Gazvoda, M., Urankar, D., Kafka, S., and Ko\u0161mrlj, J. (2018). Synthesis of Bis(1,2,3-Triazole) Functionalized Quinoline-2,4-Diones. Molecules, 23.","DOI":"10.3390\/molecules23092310"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Krstulovi\u0107, L., Mi\u0161kovi\u0107 \u0160poljari\u0107, K., Rastija, V., Filipovi\u0107, N., Baji\u0107, M., and Glava\u0161-Obrovac, L. (2023). Novel 1,2,3-Triazole-Containing Quinoline-Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking. Molecules, 28.","DOI":"10.3390\/molecules28196950"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.molstruc.2017.06.027","article-title":"Synthesis, Characterization, and Pharmacological Studies of Ferrocene-1H-1,2,3-Triazole Hybrids","volume":"1146","author":"Haque","year":"2017","journal-title":"J. Mol. Struct."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1016\/j.jorganchem.2004.04.036","article-title":"Easily Synthesized Antimalarial Ferrocene Triazacyclononane Quinoline Conjugates","volume":"689","author":"Biot","year":"2004","journal-title":"J. Organomet. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","article-title":"Antimalarial Drug Discovery: Progress and Approaches","volume":"22","author":"Wicht","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4269\/ajtmh.2007.77.181","article-title":"Artemisinin-Based Combination Treatment of Falciparum Malaria","volume":"77","author":"Nosten","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2017.04.006","article-title":"Targeting the Active Sites of Malarial Proteases for Antimalarial Drug Discovery: Approaches, Progress and Challenges","volume":"50","author":"Roy","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/cr500197d","article-title":"Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites","volume":"114","author":"Merritt","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"296ra111","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A Long-Duration Dihydroorotate Dehydrogenase Inhibitor (DSM265) for Prevention and Treatment of Malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/187152610791163336","article-title":"Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial Chemotherapy","volume":"10","author":"Phillips","year":"2010","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","article-title":"DSM265 for Plasmodium falciparum Chemoprophylaxis: A Randomised, Double-Blinded, Phase 1 Trial with Controlled Human Malaria Infection","volume":"17","author":"Sulyok","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/jix613","article-title":"A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malaria Infection by Mosquito Bites and Direct Venous Inoculation","volume":"217","author":"Murphy","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, Tolerability, Pharmacokinetics, and Activity of the Novel Long-Acting Antimalarial DSM265: A Two-Part First-in-Human Phase 1a\/1b Randomised Study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial Activity of Single-Dose DSM265, a Novel Plasmodium Dihydroorotate Dehydrogenase Inhibitor, in Patients with Uncomplicated Plasmodium falciparum or Plasmodium vivax Malaria Infection: A Proof-of-Concept, Open-Label, Phase 2a Study","volume":"18","author":"Casapia","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1473-3099(15)00343-6","article-title":"Artefenomel: A Promising New Antimalarial Drug","volume":"16","author":"Rosenthal","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e01371-19","DOI":"10.1128\/AAC.01371-19","article-title":"A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 to Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers","volume":"64","author":"McCarthy","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/jac\/dkab181","article-title":"Seeking an Optimal Dosing Regimen for OZ439\/DSM265 Combination Therapy for Treating Uncomplicated Falciparum Malaria","volume":"76","author":"Dini","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1080\/14756366.2022.2112576","article-title":"Inhibition of Toxoplasma gondii by 1,2,4-Triazole-Based Compounds:\u2009Marked Improvement in Selectivity Relative to the Standard Therapy Pyrimethamine and Sulfadiazine","volume":"37","author":"Bekier","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00436-023-07936-x","article-title":"Sulfadiazine analogs: Anti-Toxoplasma in vitro study of sulfonamide triazoles","volume":"122","author":"Arafa","year":"2023","journal-title":"Parasitol. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molbiopara.2005.07.006","article-title":"Toxoplasma gondii is capable of exogenous folate transport. A likely expansion of the BT1 family of transmembrane proteins","volume":"144","author":"Massimine","year":"2005","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1021\/jm900410u","article-title":"Triazole Inhibitors of Cryptosporidium parvum Inosine 5\u2032-Monophosphate Dehydrogenase","volume":"52","author":"Maurya","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ejmech.2018.03.033","article-title":"Synthesis, Antiamoebic Activity and Docking Studies of Metronidazole-Triazole-Styryl Hybrids","volume":"150","author":"Negi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"100561","DOI":"10.1016\/j.ijpddr.2024.100561","article-title":"Inhibition of Giardia duodenalis by Isocryptolepine\u2013Triazole Adducts and Derivatives","volume":"26","author":"Popruk","year":"2024","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI34261","article-title":"Helminth Infections: The Great Neglected Tropical Diseases","volume":"118","author":"Hotez","year":"2008","journal-title":"J. Clin. Invest."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.2147\/IDR.S332378","article-title":"Anthelmintic Resistance and Its Mechanism: A Review","volume":"14","author":"Fissiha","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_143","unstructured":"(2025, February 14). CDC\u2014Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/schistosomiasis\/about\/index.html."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00436-012-3151-z","article-title":"Susceptibility or Resistance of Praziquantel in Human Schistosomiasis: A Review","volume":"111","author":"Wang","year":"2012","journal-title":"Parasitol. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/0929867325666180926145537","article-title":"The Mechanism of Action of Praziquantel: Can New Drugs Exploit Similar Mechanisms?","volume":"27","author":"Thomas","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Abla, N., Keiser, J., Vargas, M., Reimers, N., Haas, H., and Spangenberg, T. (2017). Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005942"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"108291","DOI":"10.1016\/j.exppara.2022.108291","article-title":"Fluconazole as Schistosoma mansoni Cytochrome P450 Inhibitor: In Vivo Murine Experimental Study","volume":"239","author":"Elzoheiry","year":"2022","journal-title":"Exp. Parasitol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"108293","DOI":"10.1016\/j.exppara.2022.108293","article-title":"Itraconazole, a Cytochrome P450 Inhibitor, Enhanced the Efficacy of Praziquantel against Schistosoma mansoni Infection and Alleviated Liver Injury in Mice","volume":"239","author":"Sabra","year":"2022","journal-title":"Exp. Parasitol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cmdc.201900583","article-title":"Structure-Based Design, Synthesis, and Biological Evaluation of Triazole-Based smHDAC8 Inhibitors","volume":"15","author":"Kalinin","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Singh, S., El-Sakkary, N., Skinner, D.E., Sharma, P.P., Ottilie, S., Antonova-Koch, Y., Kumar, P., Winzeler, E., and Caffrey, C.R. (2020). Synthesis and Bioactivity of Phthalimide Analogs as Potential Drugs to Treat Schistosomiasis, a Neglected Disease of Poverty. Pharmaceuticals, 13.","DOI":"10.3390\/ph13020025"},{"key":"ref_151","first-page":"100001","article-title":"The Use of Heterocyclic-Based Azo Compounds Bearing Pyrrolidine, Imidazole, Triazole, and Thiazole Moieties for the Treatment of Neglected Tropical Disease Caused by Schistosoma mansoni","volume":"1","author":"Scarim","year":"2021","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"15867","DOI":"10.1021\/acs.jmedchem.3c01333","article-title":"Discovery of New Broad-Spectrum Anti-Infectives for Eukaryotic Pathogens Using Bioorganometallic Chemistry","volume":"66","author":"Lin","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Paprocka, R., Ko\u0142odziej, P., Wiese-Szadkowska, M., Helmin-Basa, A., and Bogucka-Kocka, A. (2022). Evaluation of Anthelmintic and Anti-Inflammatory Activity of 1,2,4-Triazole Derivatives. Molecules, 27.","DOI":"10.3390\/molecules27144488"},{"key":"ref_154","first-page":"47","article-title":"Evaluation of In Vitro Anthelmintic Activities of Novel 1,2,3-Benzotriazole Derivatives Synthesized in Ultrasonic and Solvent Free Conditions","volume":"7","author":"Sudhir","year":"2013","journal-title":"J. Pharm. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11908-022-00782-5","article-title":"Antifungal Resistance and the Role of New Therapeutic Agents","volume":"24","author":"Logan","year":"2022","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1111\/1462-2920.15274","article-title":"Mechanisms of Triazole Resistance in Aspergillus fumigatus","volume":"22","author":"Nywening","year":"2020","journal-title":"Environ. Microbiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"108206","DOI":"10.1016\/j.exppara.2021.108206","article-title":"In Vitro Selection of Ketoconazole-Pentamidine-Resistant Leishmania (Viannia) braziliensis Strains","volume":"233","author":"Escobar","year":"2022","journal-title":"Exp. Parasitol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/infdis\/jis331","article-title":"Benznidazole-Resistance in Trypanosoma cruzi Is a Readily Acquired Trait That Can Arise Independently in a Single Population","volume":"206","author":"Mejia","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molbiopara.2014.01.002","article-title":"Benznidazole-Resistance in Trypanosoma cruzi: Evidence That Distinct Mechanisms Can Act in Concert","volume":"193","author":"Campos","year":"2014","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpddr.2019.11.004","article-title":"Current Trends in the Pharmacological Management of Chagas Disease","volume":"12","author":"Ribeiro","year":"2020","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug Combination Therapy for Emerging Viral Diseases","volume":"26","author":"Shyr","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"20420986221143266","DOI":"10.1177\/20420986221143266","article-title":"Safety of Triazole Antifungals: A Pharmacovigilance Study from 2004 to 2021 Based on FAERS","volume":"13","author":"Chai","year":"2022","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S6321","article-title":"Clinical Safety and Tolerability Issues in Use of Triazole Derivatives in Management of Fungal Infections","volume":"2","author":"Neofytos","year":"2010","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Yang, Y.L., Xiang, Z.J., Yang, J.H., Wang, W.J., Xu, Z.C., and Xiang, R.L. (2021). Adverse Effects Associated with Currently Commonly Used Antifungal Agents: A Network Meta-Analysis and Systematic Review. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.697330"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.npp.1300044","article-title":"Steroid Synthesis Inhibition with Ketoconazole and Its Effect upon the Regulation of the Hypothalamus-Pituitary-Adrenal System in Healthy Humans","volume":"28","author":"Deuschle","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e1763","DOI":"10.1016\/S2214-109X(21)00392-2","article-title":"Towards the Elimination of Visceral Leishmaniasis as a Public Health Problem in East Africa: Reflections on an Enhanced Control Strategy and a Call for Action","volume":"9","author":"Alvar","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","article-title":"History of the Development of Azole Derivatives","volume":"10","author":"Maertens","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s13224-021-01586-8","article-title":"Common Antifungal Drugs in Pregnancy: Risks and Precautions","volume":"71","author":"Patel","year":"2021","journal-title":"J. Obstet. Gynaecol. India"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S1473-3099(24)00404-3","article-title":"Two Dose Levels of Once-Weekly Fosravuconazole versus Daily Itraconazole in Combination with Surgery in Patients with Eumycetoma in Sudan: A Randomised, Double-Blind, Phase 2, Proof-of-Concept Superiority Trial","volume":"24","author":"Fahal","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/1346-8138.14607","article-title":"Efficacy and Safety of Fosravuconazole L-Lysine Ethanolate, a Novel Oral Triazole Antifungal Agent, for the Treatment of Onychomycosis: A Multicenter, Double-Blind, Randomized Phase III Study","volume":"45","author":"Watanabe","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"eadg8105","DOI":"10.1126\/scitranslmed.adg8105","article-title":"Short-Course Combination Treatment for Experimental Chronic Chagas Disease","volume":"15","author":"Wall","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_172","first-page":"CD012918","article-title":"Shortened Treatment Regimens versus the Standard Regimen for Drug-Sensitive Pulmonary Tuberculosis","volume":"12","author":"Grace","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.2147\/IJN.S206109","article-title":"Advances in Nanocarriers as Drug Delivery Systems in Chagas Disease","volume":"14","author":"Azevedo","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_174","first-page":"28","article-title":"An Overview of the Treatment of Cutaneous Leishmaniasis","volume":"9","author":"Arenas","year":"2020","journal-title":"Fac. Rev."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"European Food Safety Authority (EFSA), European Centre for Disease Prevention and Control (ECDC), European Chemicals Agency (ECHA), European Environment Agency (EEA), European Medicines Agency (EMA), and European Commission\u2019s Joint Research Centre (JRC) (2025). Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant Aspergillus spp.. EFSA J., 23, e9200.","DOI":"10.2903\/j.efsa.2025.9200"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"100368","DOI":"10.1016\/j.onehlt.2021.100368","article-title":"Drug Resistant Parasites and Fungi from a One-Health Perspective: A Global Concern That Needs Transdisciplinary Stewardship Programs","volume":"14","author":"Picot","year":"2022","journal-title":"One Health"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1039\/C9MD00298G","article-title":"Repositioning Salirasib as a New Antimalarial Agent","volume":"10","author":"Porta","year":"2019","journal-title":"Medchemcomm"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","article-title":"Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics","volume":"67","author":"Dean","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Cerutti, J.P., Diniz, L.A., Santos, V.C., Vilchez Larrea, S.C., Alonso, G.D., Ferreira, R.S., Dehaen, W., and Quevedo, M.A. (2024). Structure-Aided Computational Design of Triazole-Based Targeted Covalent Inhibitors of Cruzipain. Molecules, 29.","DOI":"10.3390\/molecules29174224"},{"key":"ref_180","unstructured":"(2025, March 01). DrugBank. Available online: https:\/\/go.drugbank.com\/."},{"key":"ref_181","unstructured":"(2025, March 01). Google Scholar. Available online: https:\/\/scholar.google.com\/."},{"key":"ref_182","unstructured":"(2025, March 01). PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/."},{"key":"ref_183","unstructured":"(2025, March 01). ChEMBL. Available online: https:\/\/www.ebi.ac.uk\/chembl\/."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/5\/142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:35:35Z","timestamp":1760031335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/5\/142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":183,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["tropicalmed10050142"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed10050142","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}